Case Report

An adolescent girl in Hong Kong with type 1b Abernethy malformation complicated by multiple focal nodular hyperplasia

Max Kai Ho Yam, MBChB, FRCR, Kin On Cheung, MBBS, Shiu Wah Sim, MBBS, FCR, FHKCR, FHKAM (Radiology), Paul Sing Fun Lee, MBBS, FCR, FHKCR, FHKAM (Radiology),

A Alice Ho Miu Ling Nethersole Hospital, 11 Chuen On Road, Tui Po, NT, Hong Kong
b North District Hospital, 9 Po Kin Road, Sheung shui, New Territories, Hong Kong

ABSTRACT

Congenital portosystemic venous shunts are developmental anomalies. They represent portal communication with the systemic circulation. The pathogenesis is linked to the complexity of the embryological development of the inferior vena cava and portal vein. We reported a case of an asymptomatic 14-year-old Chinese adolescent girl in Hong Kong with a confirmed congenital portosystemic shunt type 1b. The condition can be diagnosed using contrast-enhanced CT scans and MRIs. Early recognition of the condition is important due to elevated risks of developing hepatocellular tumours. Liver transplantation may be considered curative.

© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Congenital portosystemic shunts within the hepatic parenchyma are not uncommon. Most adult patients with portosystemic shunts present with bleeding or hepatic encephalopathy as first manifestations [1]. It has been hypothesized that patients become more symptomatic with advancing age as the tolerance for high ammonia levels diminishes [2]. Ultrasound may reveal drainage of portal vein into inferior vena cava. Contrast-enhanced CT scan and MRI scan of abdomen were performed which confirmed the diagnosis of type 1b Abernethy malformation without associated major anomalies. The common clinical presentations, associated anomalies, diagnostic workup and treatment options of this disorder were discussed.

Competing interests: The authors declare that they have no competing interests.
Informed consent: Informed consent has been taken from the patient described in this case report.
Corresponding author.
E-mail address: ntecradiology@gmail.com (M.K.H. Yam).

https://doi.org/10.1016/j.radcr.2020.09.016
1930-0433/© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Liver showed heterogeneous contrast enhancement. Patchy hypoenhancing hepatic lesions were seen on both lobes in arterial and portal-venous phase, which became more isodense in the delayed phase.

Primovist (Gadoxetate disodium)-enhanced MRI scan detected absence of intrahepatic portal venous system. The splenic vein and superior mesenteric vein joined into a common vein that drained directly into the distal IVC (HV confluence region). Those findings were suggestive of type 1b congenital extrahepatic portosystemic shunt (CEPS).

Multiple focal hepatic lesions were present. Most were T1 hyperintense, T2 hypointense, with mild homogeneous arterial hyperenhancement and hyperintensity on hepatobiliary phase (Fig. 3). No washout or capsule was noted. Some lesions displayed a central feeding vessel and central scar. Findings were suggestive of focal nodular hyperplasia. On the other hand, the patient did not have other risk factors of hepatocellular carcinoma, which could be an important differential diagnosis part from focal nodular hyperplasia. She was not a hepatitis B carrier and has no history of transfusion or body tattoos. The lesions were unchanged in appearances and sizes in subsequent annual follow-up MRI scans and therefore carcinoma is unlikely.

No intervention was performed as the patient remained asymptomatic all along. The aetiology of this shunt was considered to be congenital. This extrahepatic portosystemic shunt was just part of the constellation of congenital anomalies that the patient has experienced as described in the clinical history.
In normal individuals, there are no anatomical connections between the components of the portal system and the systemic or hepatic veins within or outside the liver. Abernethy malformation is a rare condition in which portal blood is shunted into the systemic circulation via an abnormal communication of the portal system with the systemic circulation. Abernethy malformation, which was often undiagnosed, was first described in 1793 [1]. Congenital portosystemic shunts are classified into 2 major categories: total shunting with complete absence of intrahepatic portal venous flow (extrahepatic) – type I; type 1 Abernethy malformation can be further divided into subtypes 1a and 1b. In subtype 1a, the superior mesenteric vein and the splenic vein do not connect, whereas in subtype 1b, the superior mesenteric vein and splenic vein connect to form a portal vein, which then drains into a systemic vein, as in our illustrated case; In type 2 Abernethy malformation, the portal vein is intact, but a side-to-side shunting with the inferior vena cava (intrahepatic) [2].

CEPS may be asymptomatic. However, clinical features of portosystemic shunts may be related to the shunting of portal blood, associated congenital abnormalities and hepatic lesions. They are associated with multiple congenital abnormalities, with the most common involving the cardiovascular system, and include ventricular and atrial septal defects [3]. CEPS are also associated with anomalies in the gastrointestinal, genitourinary, skeletal and vascular systems. Most abnormalities are more common in type I CEPS [4], just like in our above reported case.

Symptoms related to the shunt include hepatopulmonary syndrome [5], hepatic encephalopathy of which patients may present with neurological symptoms and symptoms due to portosystemic encephalopathy and increased blood ammonia levels [6]. They can also have metabolic dysfunction, such as hyperammonemia and galactosemia [7].

Early recognition of CEPS is important. Patients with congenital agenesis of the portal vein, due to enhanced arterial blood flow, may develop hepatocellular lesions such as benign focal nodular hyperplasia, hepatocellular adenoma and regenerative nodules [8–11].

Hepatocellular carcinoma has been reported by a number of authors as an association with the Abernethy malformation [12]. There has been an increase in the diagnosis of the condition with modern advances in medical imaging. Early noninvasive cross-sectional images via Doppler ultrasound, computed tomography or magnetic resonance imaging is key to providing an accurate diagnosis and classification, further directing the therapeutic course and clinical outcome.

Imaging plays a significant role in diagnosis, classification, and treatment of these patients. Early noninvasive cross-sectional images via Doppler ultrasound, computed tomography or magnetic resonance imaging are useful in pre- and post-treatment imaging as well as imaging of its complications [13].

There is no consensus guideline for the optimal management of patients with CEPS.

According to the type of shunt, symptomatic patients were divided into 2 groups. Liver transplants may be considered with type 1 shunts, whereas shunt closure (eg, interventional embolization or surgery) may be chosen for those with type 2 shunts [14].

Jaklitsch et al. [15] noted that half of individuals with Abernethy malformation type 1b would develop one or multiple types of tumours, ranging from benign to malignant liver tumours. It could be interpreted as a common finding for a rare disease.

As mentioned earlier, hyperarterialization of the liver could be a postulated cause of the increased risks of developing liver tumours, therefore, curative resection or orthotopic liver
transplantation if recommended might alter the course of disease into better long-term outcome.

REFERENCES

[1] Pathak A, Agarwal N, Mandliya J, et al. Abernethy malformation: a case report. BMC Pediatr 2012;12:57. doi:10.1186/1471-2431-12-57.

[2] Ghuman Samarjit S, Gupta Saumya, Buxi TBS, Rawat Kishan S, Yadav Anurag, Mehta Naimish, et al. The Abernethy malformation—myriad imaging manifestations of a single entity. Indian J Radiol Imaging 2016;26(3):364–72. doi:10.4103/0971-2431.190420.

[3] Kanamori Y, Hashizume K, Kitano Y, Sugiyama M, Motoi T, Tange T. J Pediatr Surg 2003;38(4):E15. doi:10.1053/jpsu.2003.50153.

[4] Murray CP, Yoo SJ, Babyn PS. Congenital extrahepatic portosystemic shunts. Pediatr Radiol 2003;33:614–20.

[5] Alvarez AE, Ribeiro AF, Hessel G, Baracat J, Ribeiro JD. Abernethy malformation: one of the etiologies of hepatopulmonary syndrome. Pediatr Pulmonol 2002;34:391–4.
[6] Witters P, Maleux G, George C, Delcroix M, Hoffman I, Gewillig M, et al. Congenital veno-venous malformations of the liver: widely variable clinical presentations. J Gastroenterol Hepatol 2008;23(Pt 2):e390–4.

[7] Franchi-Abella S, Branchereau S, Lambert V, Fabre M, Steimberg C, Losay J, et al. Complications of congenital portosystemic shunts in children: therapeutic options and outcomes. J Pediatr Gastroenterol Nutr 2010;51:322–30.

[8] Guariso G, Fiorio S, Altavilla G, Gamba PG, Toffolutti T, Chiesura-Corona M, et al. Congenital absence of the portal vein associated with focal nodular hyperplasia of the liver and cystic dysplasia of the kidney. Eur J Pediatr. 1998;157(4):287–90. doi:10.1007/s004310050812.

[9] Collard B, Maleux G, Heye S, Cool M, Bielen D, George C, et al. Value of carbon dioxide wedged venography and transvenous liver biopsy in the definitive diagnosis of Abernethy malformation. Abdom Imaging 2006;31(3):315–19. doi:10.1007/s00261-005-0151-9.

[10] Kinjo T, Aoki H, Sunagawa H, Kinjo S, Muto Y. Congenital absence of the portal vein associated with focal nodular hyperplasia of the liver and congenital choledochal cyst: a case report. J Pediatr Surg 2001;36:622–5.

[11] Christou N, Dib N, Chuffart E, Abdelkader Taibi, Sylvaine Durand Fontanier, Denis Valieux, et al. Stepwise management of hepatocellular carcinoma associated with Abernethy syndrome. Clin Case Rep 2018;6(5):930–4. doi:10.1002/ccr3.1384.

[12] Pichon N, Maisonnette F, Pichon-Lefèvre F, Valieux D, Pillégand B. Hepatocarcinoma with congenital agenesis of the portal vein. Jpn J Clin Oncol 2003;33:314–16.

[13] Alonso-Gamarra E, Parrón M, Pérez A, Prieto C, Hierro L, López-Santamaría M. Clinical and radiologic manifestations of congenital extrahepatic portosystemic shunts: a comprehensive review. Radiographics 2011;31:707–22.

[14] Akahoshi T, Nishizaki T, Wakasugi K, Mastuza T, Kume K, Yamamoto I, et al. Portal-systemic encephalopathy due to a congenital extrahepatic portosystemic shunt: three cases and literature review. Hepatogastroenterology 2000;47:1113–16.

[15] Jaklitsch M, Sobral M, Carvalho AM, Marques HP, et al. Abernethy malformation and hepatocellular carcinoma: a serious consequence of a rare disease. BMJ Case Rep 2020;13:e231843. doi:10.1136/bcr-2019-231843.